Philips launches IntelliSpace Discovery* Research platform at RSNA to support the development and deployment of Artificial Intelligence assets in radiology

Amsterdam, the Netherlands – Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Royal Philips, a global leader in health technology, today announced the introduction of IntelliSpace Discovery 3.0, a comprehensive, open platform to enable the development and deployment of Artificial Intelligence assets in radiology with the aim to support radiologists in their clinical and translational research.

Solutions that leverage AI have the potential to improve patient care and increase the efficiency of care delivery. However, there are challenges when it comes to introducing AI into healthcare clinical practice. Health systems are consistently faced with questions on how to collect and prepare high quality data, which methods of training and validating the tools are most appropriate, and how to deploy AI without disruption. Philips combines AI and other technologies with knowledge of the clinical and operational context in which they are used – a people-centered approach called ‘adaptive intelligence’ – to develop integrated solutions that adapt to the needs of healthcare providers.

AI for Radiology

IntelliSpace Discovery is already a proven research platform, used by more than 50 hospitals and academic institutions worldwide, for the development of radiology applications for rendering, segmentation, and quantification. For example, it is being used for research and clinical validation and subsequently the tools/applications can be deployed into the radiology workflow on the Philips IntelliSpace Portal [1]. With the introduction of IntelliSpace Discovery 3.0 the platform now provides research applications and tools for radiologists to aggregate, normalize and anonymize data, which can be visualized and annotated to ‘train’ and validate deep learning algorithms. They can then easily deploy these algorithms as plug-in apps into the research workflow to analyze new datasets and help facilitate clinical research in radiology, oncology, neurology and cardiology.

“We use IntelliSpace Discovery to bring our research activities to the next level. Everybody is talking about Artificial Intelligence. We are making our own deep learning AI algorithms,” said

Professor David Maintz, Head of the Department of Radiology of the University Hospital Cologne in Germany.

“Together with our customers we’re enabling research in adaptive intelligence with the goal to create solutions that augment healthcare professionals and improve patient care and efficiencies of care delivery, both inside and outside of the hospital,” said Jeroen Tas, Chief Innovation & Strategy Officer, Philips. “AI is the connective tissue to seamlessly integrate data and technology to enable precision diagnosis. At RSNA 2018 we’re showing how AI is laying the foundations for solutions of the future.”

The building blocks of IntelliSpace Discovery* include:

  • Front End Applications – Integration with existing clinical infrastructure provides seamless access to vendor agnostic and multi-modality data-sets, and research advanced visualization tools allow data to be prepared and processed for AI training with existing AI tools.
  • Study Management – Fully scalable infrastructure contains a vendor neutral research archive for structured and unstructured data, used to upload and process data.
  • Machine Learning – Research data and deployment platform obtains batch processing in a scalable high-performance computing environment to support iterative development and validation.
  • Clinical Research – AI assets and capabilities include multi-parametric enablement, segmentation and annotation, tumor quantification and stratification, deep learning networks and classification.
  • Research Services –Accessibility to Philips R&D for a range of services from consultancy to development.

Another example of a solution showcased at RSNA that is powered by adaptive intelligence is Philips Illumeo. Pulling data from various hospital sources, this intelligent software presents a holistic view of the patient and provides relevant tools that adapt to physician needs, offering insights and standardizing their workflow based on their own preferences. A press backgrounder with more information how Philips pioneers adaptive intelligence in health technology to advance value-based healthcare can be found here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.